|  |
| --- |
| **Supplemental Table 2. Mean Difference (95% CI) Between Fezolinetant and Placeboa in Greene Climacteric Scale (GCS)** |
| **Parameters** | **Fezolinetant** |
| **15 mgBID(n=45)** | **30 mg BID(n=43)** | **60 mg BID(n=45)** | **90 mg BID(n=44)** | **30 mg QD(n=43)** | **60 mg QD(n=45)** | **120 mg QD(n=44)** |
| Week 4, n | 42 | 41 | 40 | 39 | 39 | 41 | 40 |
| Total score | −1.8(−4.8, 1.3) | −3.6(−6.6, −0.5) | −4.3(−7.4, −1.3) | −3.4(−6.5, −0.3) | −1.5(−4.6, 1.5) | 0.2(−2.8, 3.3) | −4.2(−7.3, −1.2) |
| Psychological symptoms | −1.1(−2.9, 0.7) | −1.9(−3.7, −0.1) | −2.4(−4.2, −0.5) | −1.8(−3.6, 0) | −1.0(−2.8, 0.8) | 0.6(−1.2, 2.4) | −2.2(−4.0, −0.4) |
| Physical symptoms | 0(−1.0, 1.0) | −0.5(−1.5, 0.5) | 0(−1.0, 1.0) | 0(−1.1, 1.0) | −0.3(−1.3, 0.7) | 0.3(−0.7, 1.3) | −0.8(−1.8, 0.2) |
| Vasomotor symptoms | −0.5(−1.2, 0.2) | −1.0(−1.7, −0.3) | −1.6(−2.3, −0.9) | −1.5(−2.2, −0.8) | −0.5(−1.2, 0.2) | −0.9(−1.6, −0.2) | −1.2(−1.9, −0.5) |
| Sexual dysfunction | −0.4(−0.7, 0) | −0.4(−0.7, 0) | −0.5(−0.8, −0.2) | −0.3(−0.7, 0) | 0(−0.3, 0.4) | 0(−0.4, 0.3) | −0.3(−0.6, 0.1) |
| Week 12, n | 40 | 33 | 30 | 29 | 29 | 34 | 36 |
| Total score | −2.8(−6.0, 0.4) | −2.5(−5.7, 0.7) | −3.0(−6.3, 0.3) | −2.6(−5.9, 0.7) | −1.9(−5.2, 1.4) | −0.2(−3.4, 3.0) | −2.6(−5.9, 0.6) |
| Psychological symptoms | −1.7(−3.6, 0.2) | −1.5(−3.5, 0.4) | −1.5(−3.5, 0.5) | −0.9(−2.9, 1.0) | −1.1(−3.1, 0.8) | −0.3(−2.2, 1.6) | −1.6(−3.5, 0.3) |
| Physical symptoms | −0.6(−1.6, 0.4) | 0.5(−0.5, 1.5) | 0.2(−0.8, 1.3) | −0.1(−1.2, 0.9) | −0.1(−1.2, 0.9) | 0.6(−0.4, 1.7) | −0.4(−1.4, 0.6) |
| Vasomotor symptoms | −0.5(−1.2, 0.2) | −1.0(−1.7, −0.3) | −1.5(−2.2, −0.8) | −1.5(−2.2, −0.8) | −0.8(−1.5, −0.1) | −0.7(−1.4, 0) | −0.8(−1.5, −0.1) |
| Sexual dysfunction | −0.2(−0.6, 0.2) | −0.6(−1.0, −0.2) | −0.4(−0.8, 0) | −0.3(−0.7, 0.1) | −0.1(−0.4, 0.3) | 0(−0.4, 0.4) | −0.1(−0.5, 0.3) |
| Data are least squares (LS) mean differences from placebo (95% confidence intervals). A negative value indicates improvement. The LS means and confidence intervals come from a mixed model for repeated measurements model with change from baseline as the dependent variable and the treatment group, visit and smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week and an interaction of baseline measurement by week. aOf 43 participants in the placebo group, 41 contributed data to the total score at week 4 and 36 contributed to the total score at week 12. |